Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Textual)

v2.4.0.6
Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2012
Segment
Organization and Summary of Significant Accounting Policies (Additional Textual) [Abstract]    
Number of operating business segments   1
Domestic revenue of sublingual buprenorphine formulations   $ 1,300,000,000
Non-cash loss on an increase in the fair value $ 3,673,000  
Iloperidone patent expiry year   2016-10
Minimum [Member]
   
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]    
Royalty revenue percentage   8.00%
Maximum [Member]
   
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]    
Royalty revenue percentage   10.00%